Crinetics Pharmaceuticals, Inc

(NASDAQ:CRNX)

Latest On Crinetics Pharmaceuticals, Inc (CRNX):

Date/Time Type Description Signal Details
2023-05-25 19:43 ESTNewsCrinetics Pharmaceuticals And Its Value Proposition In AcromegalyN/A
2023-05-04 23:54 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.85 misses by $0.01, revenue of $2.67M beats by $2.43MN/A
2023-03-06 12:48 ESTNewsEvaluating Crinetics' Oral Long Shot For AcromegalyN/A
2023-02-28 18:44 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.84 misses by $0.01, revenue of $0.71M beats by $0.41MN/A
2022-12-30 22:15 ESTNewsCrinetics: FY23 Could Be Turning Point With Two Phase 3 Acromegaly ReadoutsN/A
2022-11-29 04:07 ESTNewsCrinetics says FDA didn’t clear Phase 2 study request for hyperinsulinism drugN/A
2022-11-15 00:39 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.78 beats by $0.03, revenue of $0.46M beats by $0.26MN/A
2022-08-12 17:31 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28MN/A
2022-06-13 22:31 ESTNewsCrinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection PointN/A
2022-05-25 15:30 ESTNewsCrinetics hormone CRN04894 therapy shows promise in early-stage studyN/A
2022-05-13 09:56 ESTNewsCrinetics Pharmaceuticals GAAP EPS of -$0.73 misses by $0.17, revenue of $3.13M misses by $2.07MN/A
2022-04-29 23:10 ESTNewsCrinetics: An Orphan Disease Innovator On The RiseN/A
2022-04-24 11:40 ESTNewsCrinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes ProgressN/A
2022-04-13 16:17 ESTNewsCrinetics Pharmaceuticals prices $125M stock offeringN/A
2022-04-01 04:52 ESTNewsCrinetics stock gains on hyperinsulinism candidate's trial data; JMP raises PTN/A
2022-03-31 09:08 ESTNewsCrinetics Pharmaceuticals reports resultsN/A
2022-03-30 16:39 ESTNewsCrinetics shows dose-dependent effect of hyperinsulinism candidate in early trialN/A
2022-03-18 16:25 ESTNewsCrinetics delays early Phase 1 data for experimental therapy due to COVID-19N/A
2022-02-28 09:07 ESTNewsCrinetics, Sanwa ink licensing deal for cancer/hormonal disorder drug in JapanN/A
2021-10-22 05:14 ESTNewsCrinetics Pharmaceuticals prices $150M in stock offeringN/A
2021-10-21 03:29 ESTNewsCrinetics drops after announcing common stock offeringN/A
2021-09-21 15:29 ESTNewsCrinetics posts preliminary results from early-stage CRN04777 hyperinsulinism studyN/A
2021-09-21 15:23 ESTNewsCrinetics Pharmaceuticals (CRNX) Investor Presentation - SlideshowN/A
2021-09-02 17:30 ESTNewsCrinetics Pharmaceuticals names Jeff Knight as chief operating officerN/A
2021-08-10 23:06 ESTNewsCrinetics Pharmaceuticals posts positive data from early-stage CRN04894 trialN/A
2021-08-10 23:05 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.10N/A
2021-07-29 16:43 ESTNewsCrinetics Pharmaceuticals proposes $15M in private placement with Frazier HealthcareN/A
2021-07-21 02:52 ESTNewsCrinetics doses first patient in late-stage oral paltusotine acromegaly trialN/A
2021-05-07 06:27 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.04N/A
2021-04-08 07:33 ESTNewsCrinetics Pharma raises $75M via equity offeringN/A
2021-03-30 23:41 ESTNewsCrinetics Pharmaceuticals, Inc. (CRNX) CEO Scott Struthers on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-30 23:41 ESTNewsCrinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationN/A
2021-01-23 04:21 ESTNewsCrinetics Pharmaceuticals (CRNX) Presents At 39th Annual J.P. Morgan Healthcare Conference - SlideshowN/A
2020-12-13 03:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 07:37 ESTAnalyst RatingThe Analyst Target Price has increased from $32.8 to $33.6.Buy
2020-11-09 11:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 11:40 ESTEarnings EstimateAn EPS average of -$0.59 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-07 15:30 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 06:16 ESTNewsCrinetics Pharmaceuticals EPS misses by $0.03N/A
2020-10-30 12:37 ESTAnalyst RatingThe Analyst Target Price has decreased from $36.75 to $32.8.Neutral
2020-10-26 14:41 ESTNewsCrinetics Pharma lead drug successful in mid-stage acromegaly studyN/A
2020-09-26 12:27 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:35 ESTFinancialsCompany financials have been released.Neutral
2020-09-08 04:25 ESTAnalyst RatingThe Analyst Target Price has decreased from $36.8 to $36.75.Neutral
2020-09-05 01:11 ESTNewsCrinetics Pharma to advance ACTH antagonist candidate into the clinicN/A
2020-09-05 00:31 ESTFinancialsCompany financials have been released.Neutral
2020-09-02 11:29 ESTNewsCrinetics Pharmaceuticals- Superior Molecules In EndocrinologyN/A
2020-08-09 08:28 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 16:03 ESTNewsCrinetics Pharmaceuticals EPS beats by $0.02N/A
2020-07-31 00:39 ESTFinancialsCompany financials have been released.Neutral

About Crinetics Pharmaceuticals, Inc (CRNX):

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

CRNX Quotes by TradingView

See Advanced Chart

General

  • Name Crinetics Pharmaceuticals, Inc
  • Symbol CRNX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 68
  • Fiscal Year EndDecember
  • IPO Date2018-07-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.crinetics.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1102.47
  • Price/Book (Most Recent Quarter) 2.99
  • Enterprise Value Revenue 961.96
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.55
  • Operating Margin -17443%
  • Return on Assets -25%
  • Return on Equity -42%
  • Revenue 392000
  • Earnings Per Share -$1.62
  • Revenue Per Share $0.01
  • Gross Profit -40313000
  • Quarterly Earnings Growth -80.7%
View More

Highlights

  • Market Capitalization 531.37 million
  • EBITDA -40113000
  • PE Ratio -16.54
  • Analyst Target Price $33.6
  • Book Value Per Share $5.69
View More

Share Statistics

  • Shares Outstanding 32.92 million
  • Shares Float 20.69 million
  • % Held by Insiders 450%
  • % Held by Institutions 95.14%
  • Shares Short 1.53 million
  • Shares Short Prior Month 1.38 million
  • Short Ratio 13.29
  • Short % of Float 6%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.23
  • 52 Week High $23.7
  • 52 Week Low $11.61
  • 50 Day Moving Average 15.77
  • 200 Day Moving Average 14.69
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Crinetics Pharmaceuticals, Inc (CRNX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Crinetics Pharmaceuticals, Inc (CRNX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-06$N/A-$0.56-$0.53-6.38%
2020-06-302020-08-07$N/A-$0.53-$0.554.21%
2020-03-312020-05-08$N/A-$0.71-$0.63-12.66%
2019-12-312020-03-09$321000-$0.60-$0.6811.35%
2019-09-302019-11-12$505000-$0.60-$0.54-11.92%
2019-06-302019-08-13$N/A-$0.51-$0.46-11.79%
2019-03-312019-05-13$367000-$0.37-$0.394.61%
2018-12-312019-03-13$781000-$0.35-$0.4115.09%
2018-09-302018-11-13$548000-$0.38-$0.34-10.47%
2018-06-302018-08-30$657000-$0.33-$0.31-7.32%

Crinetics Pharmaceuticals, Inc (CRNX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Crinetics Pharmaceuticals, Inc (CRNX) Chart:

CRNX chart by TradingView

Crinetics Pharmaceuticals, Inc (CRNX) News:

Below you will find a list of latest news for Crinetics Pharmaceuticals, Inc (CRNX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Crinetics Pharmaceuticals, Inc (CRNX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172026.1CALL0 1300.92TRUE00
2024-05-1722.50CALL0 0284.75TRUE00
2024-05-17250CALL0 0220.36TRUE00
2024-05-173014.27CALL0 2173.63TRUE00
2024-05-173510.5CALL0 17133.61TRUE00
2024-05-17402.95CALL0 4497.56TRUE00
2024-05-17453.5CALL5 16358.15TRUE3.50
2024-05-17501CALL36 22558.81FALSE0.350.54
2024-05-17550.15CALL0 5957.48FALSE00
2024-05-17600.1CALL0 550FALSE00
2024-05-17650CALL0 00FALSE00
2024-05-17700CALL0 00FALSE00
2024-05-17200PUT0 00FALSE00
2024-05-1722.50.65PUT0 10FALSE00
2024-05-17250.8PUT0 10FALSE00
2024-05-17300.1PUT0 830FALSE00
2024-05-17350.3PUT0 640FALSE00
2024-05-17400.7PUT0 2385108.12FALSE00
2024-05-17451.53PUT2 23265.5FALSE1.530
2024-05-17505.2PUT0 2577.37TRUE00
2024-05-17559.7PUT0 1067.07TRUE00
2024-05-17600PUT0 0115.12TRUE00
2024-05-17650PUT0 0112.44TRUE00
2024-05-17700PUT0 0156.75TRUE00
2024-06-21150CALL0 0199.27TRUE00
2024-06-2117.50CALL0 0168.57TRUE00
2024-06-212014.03CALL0 5154.32TRUE00
2024-06-2122.513.7CALL0 2130.93TRUE00
2024-06-212511.1CALL0 2113.5TRUE00
2024-06-213011.6CALL0 9299.63TRUE00
2024-06-21357.8CALL0 4181.79TRUE00
2024-06-21406.1CALL0 39164.74TRUE00
2024-06-21454.6CALL4 86551.6TRUE0.60.15
2024-06-21501.5CALL0 14963.42FALSE00
2024-06-21550.85CALL1 207055.12FALSE0.850
2024-06-21601.15CALL0 2153.04FALSE00
2024-06-21650.59CALL0 667.79FALSE00
2024-06-21700.38CALL0 10FALSE00
2024-06-21150PUT0 00FALSE00
2024-06-2117.50PUT0 00FALSE00
2024-06-21200.5PUT0 30FALSE00
2024-06-2122.50.15PUT0 00FALSE00
2024-06-21250.98PUT0 130FALSE00
2024-06-21301.7PUT0 30070FALSE00
2024-06-21351.15PUT0 2273.89FALSE00
2024-06-21402.12PUT0 26857.23FALSE00
2024-06-21454.4PUT0 3364.16FALSE00
2024-06-21505.9PUT0 9848.13TRUE00
2024-06-21550PUT0 066.56TRUE00
2024-06-21600PUT0 084.61TRUE00
2024-06-21650PUT0 077.73TRUE00
2024-06-21700PUT0 076.76TRUE00
2024-09-202026.8CALL0 8101.85TRUE00
2024-09-2022.50CALL0 082.71TRUE00
2024-09-202518.3CALL0 1583.26TRUE00
2024-09-20300CALL0 069.08TRUE00
2024-09-203515.3CALL0 760.56TRUE00
2024-09-20409.45CALL5 7065.49TRUE9.450
2024-09-20455.3CALL0 6859.67TRUE00
2024-09-20505.1CALL2 24454.23FALSE0.990.24
2024-09-20552.03CALL0 106354.94FALSE00
2024-09-20602.05CALL1 117048.81FALSE2.050
2024-09-20650.93CALL0 5248.93FALSE00
2024-09-20701.15CALL0 1059.79FALSE00
2024-09-20200.95PUT0 10FALSE00
2024-09-2022.51.5PUT0 20FALSE00
2024-09-20250.1PUT0 140FALSE00
2024-09-20301.05PUT0 2478.26FALSE00
2024-09-20352.5PUT0 3166.64FALSE00
2024-09-20403.5PUT0 250.8FALSE00
2024-09-20456.2PUT0 2346.51FALSE00
2024-09-20507.65PUT0 2253.27TRUE00
2024-09-20550PUT0 054.4TRUE00
2024-09-20600PUT0 055.53TRUE00
2024-09-206518PUT5 1457.45TRUE180
2024-09-20700PUT0 052.3TRUE00
2024-12-20250CALL0 069.49TRUE00
2024-12-20300CALL0 063.21TRUE00
2024-12-20350CALL0 060.26TRUE00
2024-12-20360CALL0 053.67TRUE00
2024-12-20370CALL0 059.81TRUE00
2024-12-20380CALL0 054.38TRUE00
2024-12-20390CALL0 058.29TRUE00
2024-12-20400CALL0 055.9TRUE00
2024-12-20410CALL0 057.92TRUE00
2024-12-20420CALL0 057.32TRUE00
2024-12-20430CALL0 057.37TRUE00
2024-12-20440CALL0 056.15TRUE00
2024-12-20459.2CALL3 352.3TRUE9.20
2024-12-20460CALL0 058.08TRUE00
2024-12-20477.36CALL5 052.31FALSE7.360
2024-12-20480CALL0 052.11FALSE00
2024-12-20490CALL0 054.18FALSE00
2024-12-20500CALL0 055.41FALSE00
2024-12-20550CALL0 050.75FALSE00
2024-12-20600CALL0 049.92FALSE00
2024-12-20652.05CALL0 150.06FALSE00
2024-12-20250PUT0 077.07FALSE00
2024-12-20302PUT0 1056.63FALSE00
2024-12-20350PUT0 057.36FALSE00
2024-12-20360PUT0 052.93FALSE00
2024-12-20370PUT0 057.46FALSE00
2024-12-20384.7PUT0 152.83FALSE00
2024-12-20394.5PUT0 148.33FALSE00
2024-12-20400PUT0 049.47FALSE00
2024-12-20410PUT0 051.73FALSE00
2024-12-20420PUT0 053.06FALSE00
2024-12-20430PUT0 051.5FALSE00
2024-12-20440PUT0 046.16FALSE00
2024-12-20457.71PUT0 1048.83FALSE00
2024-12-20460PUT0 053FALSE00
2024-12-20470PUT0 053.05TRUE00
2024-12-20489.9PUT0 050.89TRUE00
2024-12-20490PUT0 051.71TRUE00
2024-12-20500PUT0 051.7TRUE00
2024-12-20550PUT0 052.86TRUE00
2024-12-20600PUT0 049.62TRUE00
2024-12-20650PUT0 051.7TRUE00

Latest CRNX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$17.17
Jun 13, 2022 7:59 PM EST100$17.19
Jun 13, 2022 7:59 PM EST1$17.17
Jun 13, 2022 7:59 PM EST100$17.2
Jun 13, 2022 7:59 PM EST100$17.2

Crinetics Pharmaceuticals, Inc (CRNX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038179/0001209191-20-038179-index.htm
2018-07-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1658247/000000000018021079/0000000000-18-021079-index.htm
2019-08-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1658247/000000000019012560/0000000000-19-012560-index.htm
2018-09-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506618002299/0000315066-18-002299-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506619000968/0000315066-19-000968-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000031506620000861/0000315066-20-000861-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019963/0000899243-18-019963-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019964/0000899243-18-019964-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019965/0000899243-18-019965-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019967/0000899243-18-019967-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019968/0000899243-18-019968-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019972/0000899243-18-019972-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019974/0000899243-18-019974-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019975/0000899243-18-019975-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019978/0000899243-18-019978-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318019979/0000899243-18-019979-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924318020264/0000899243-18-020264-index.htm
2019-02-125Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924319003318/0000899243-19-003318-index.htm
2019-02-125Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924319003326/0000899243-19-003326-index.htm
2020-04-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000089924320010940/0000899243-20-010940-index.htm
2018-07-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000094787118000610/0000947871-18-000610-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518000919/0001012975-18-000919-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518000925/0001012975-18-000925-index.htm
2018-08-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000101297518001046/0001012975-18-001046-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918045567/0001104659-18-045567-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918045579/0001104659-18-045579-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918046292/0001104659-18-046292-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2018-07-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465918048071/0001104659-18-048071-index.htm
2019-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2019-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919006113/0001104659-19-006113-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919008632/0001104659-19-008632-index.htm
2019-02-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919010154/0001104659-19-010154-index.htm
2019-03-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465920011470/0001104659-20-011470-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000110465920021136/0001104659-20-021136-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000114420419008307/0001144204-19-008307-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000117266120000650/0001172661-20-000650-index.htm
2018-07-128-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518216421/0001193125-18-216421-index.htm
2018-07-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312518217820/0001193125-18-217820-index.htm
2018-07-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312518217824/0001193125-18-217824-index.htm
2018-07-17S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518219860/0001193125-18-219860-index.htm
2018-07-18424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1658247/000119312518220701/0001193125-18-220701-index.htm
2018-07-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1658247/000119312518220704/0001193125-18-220704-index.htm
2018-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518222517/0001193125-18-222517-index.htm
2018-07-30SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312518231543/0001193125-18-231543-index.htm
2018-08-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312518259557/0001193125-18-259557-index.htm
2018-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518263610/0001193125-18-263610-index.htm
2018-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518289506/0001193125-18-289506-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312518325476/0001193125-18-325476-index.htm
2019-08-13S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1658247/000119312519220012/0001193125-19-220012-index.htm
2019-08-19S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1658247/000119312519224488/0001193125-19-224488-index.htm
2019-08-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312519224495/0001193125-19-224495-index.htm
2019-08-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1658247/000119312519230761/0001193125-19-230761-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520099551/0001193125-20-099551-index.htm
2020-04-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1658247/000119312520107151/0001193125-20-107151-index.htm
2020-04-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520107156/0001193125-20-107156-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000119312520108092/0001193125-20-108092-index.htm
2020-04-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1658247/000119312520108096/0001193125-20-108096-index.htm
2020-04-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1658247/000119312520111625/0001193125-20-111625-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018982/0001209191-19-018982-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018983/0001209191-19-018983-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119018984/0001209191-19-018984-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038894/0001209191-19-038894-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038896/0001209191-19-038896-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038897/0001209191-19-038897-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038902/0001209191-19-038902-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119038905/0001209191-19-038905-index.htm
2019-07-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119042285/0001209191-19-042285-index.htm
2019-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119042286/0001209191-19-042286-index.htm
2019-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119045039/0001209191-19-045039-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008269/0001209191-20-008269-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008272/0001209191-20-008272-index.htm
2020-02-115Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120008280/0001209191-20-008280-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012974/0001209191-20-012974-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012987/0001209191-20-012987-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120012997/0001209191-20-012997-index.htm
2020-03-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120021372/0001209191-20-021372-index.htm
2020-04-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120026196/0001209191-20-026196-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038153/0001209191-20-038153-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038161/0001209191-20-038161-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038166/0001209191-20-038166-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038172/0001209191-20-038172-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120038179/0001209191-20-038179-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2020-09-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120049508/0001209191-20-049508-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000120919120049518/0001209191-20-049518-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-02-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-02-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020003601/0001213900-20-003601-index.htm
2020-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-06-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000121390020014709/0001213900-20-014709-index.htm
2018-07-12CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1658247/000135445718000250/0001354457-18-000250-index.htm
2018-08-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459018022504/0001564590-18-022504-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459018029304/0001564590-18-029304-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019007555/0001564590-19-007555-index.htm
2019-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1658247/000156459019007561/0001564590-19-007561-index.htm
2019-04-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019011511/0001564590-19-011511-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1658247/000156459019013719/0001564590-19-013719-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1658247/000156459019013723/0001564590-19-013723-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019018827/0001564590-19-018827-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019018831/0001564590-19-018831-index.htm
2019-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019023431/0001564590-19-023431-index.htm
2019-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019025016/0001564590-19-025016-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019031797/0001564590-19-031797-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019031801/0001564590-19-031801-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459019042893/0001564590-19-042893-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459019042900/0001564590-19-042900-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000156459020004205/0001564590-20-004205-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020009362/0001564590-20-009362-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1658247/000156459020009365/0001564590-20-009365-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1658247/000156459020019202/0001564590-20-019202-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1658247/000156459020019210/0001564590-20-019210-index.htm
2020-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020023260/0001564590-20-023260-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020023265/0001564590-20-023265-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020030117/0001564590-20-030117-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020038067/0001564590-20-038067-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020038069/0001564590-20-038069-index.htm
2020-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020042431/0001564590-20-042431-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020044046/0001564590-20-044046-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020047499/0001564590-20-047499-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1658247/000156459020051684/0001564590-20-051684-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1658247/000156459020051686/0001564590-20-051686-index.htm
2018-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006600/0001615774-18-006600-index.htm
2018-07-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2018-07-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1658247/000161577418006903/0001615774-18-006903-index.htm
2019-03-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1658247/999999999518001811/9999999995-18-001811-index.htm
2019-08-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1658247/999999999519002011/9999999995-19-002011-index.htm

Crinetics Pharmaceuticals, Inc (CRNX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Crinetics Pharmaceuticals, Inc (CRNX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 450%
Institutional Ownership: 9514%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-03-185AM Ventures IV, L.P.10% Share HolderSell6,194.0024.25150,208.84104,489.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2019-08-05Richard Scott StruthersPresident & CEOBuy10,000.001.9119,100.001,225,805.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119045039/0001209191-19-045039-index.htm
2019-12-16Matthew K FustDirectorSell3,500.0022.5078,750.0012,536.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2019-01-225AM Ventures IV, L.P.10% Share HolderSell10,486.0021.88229,381.25129,483.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2018-07-205AM Ventures IV, L.P.10% Share HolderBuy4,600.0017.0078,200.00139,969.00https://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy141,177.0017.002,400,009.00141,177.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2019-12-16Matthew K FustDirectorBuy3,500.001.916,685.0016,036.00https://www.sec.gov/Archives/edgar/data/1658247/000120919119061184/0001209191-19-061184-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell133.0019.502,593.50168,165.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell5,904.0021.40126,345.60168,298.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell4,614.0022.00101,508.00174,202.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell10,519.0022.80239,833.20178,816.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell4,220.0021.7091,574.00189,335.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell5,940.0022.10131,274.00193,555.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell10,878.0022.20241,491.60199,495.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2018-07-20Alan Seth KrasnerChief Medical OfficerBuy2,000.0017.0034,000.002,000.00https://www.sec.gov/Archives/edgar/data/1658247/000089924318020264/0000899243-18-020264-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell83,984.0022.251,868,644.00210,373.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2020-04-17Vivo Capital VIII, LLC10% Share HolderSell74,333.0015.401,144,728.202,162,587.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-04-16Vivo Capital VIII, LLC10% Share HolderSell26,527.0015.20403,210.402,236,920.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2020-04-15Vivo Capital VIII, LLC10% Share HolderSell189,625.0015.502,939,187.502,263,447.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2019-06-215AM Ventures IV, L.P.InsiderSell240,000.0022.205,328,000.002,267,797.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2018-07-20PERCEPTIVE ADVISORS LLCDirectorBuy400,000.0017.006,800,000.002,280,305.00https://www.sec.gov/Archives/edgar/data/1658247/000101297518000925/0001012975-18-000925-index.htm
2020-04-07Vivo Capital VIII, LLC10% Share HolderSell5,373.0014.2076,296.602,453,072.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-03Vivo Capital VIII, LLC10% Share HolderSell263,600.0013.803,637,680.002,458,445.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2019-03-185AM Ventures IV, L.P.10% Share HolderSell148,645.0024.253,604,745.302,507,797.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919016338/0001104659-19-016338-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell347.0019.506,766.502,722,045.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell1,451.0021.4031,051.402,722,392.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell1,134.0022.0024,948.002,723,843.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell2,584.0022.8058,915.202,724,977.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell1,037.0021.7022,502.902,727,561.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell1,459.0022.1032,243.902,728,598.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell2,673.0022.2059,340.602,730,057.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell292,609.0022.256,510,550.252,732,730.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy153,180.0020.733,175,421.40294,357.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-04-17Vivo Capital VIII, LLC10% Share HolderSell10,265.0015.40158,081.00298,625.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy51,686.0017.00878,662.003,025,339.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-04-16Vivo Capital VIII, LLC10% Share HolderSell3,663.0015.2055,677.60308,890.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2019-01-225AM Ventures IV, L.P.10% Share HolderSell251,667.0021.885,505,215.633,107,642.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919003219/0001104659-19-003219-index.htm
2020-04-15Vivo Capital VIII, LLC10% Share HolderSell26,185.0015.50405,867.50312,553.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020009500/0001213900-20-009500-index.htm
2018-07-205AM Ventures IV, L.P.10% Share HolderBuy110,400.0017.001,876,800.003,359,309.00https://www.sec.gov/Archives/edgar/data/1658247/000110465918046330/0001104659-18-046330-index.htm
2020-04-07Vivo Capital VIII, LLC10% Share HolderSell742.0014.2010,536.40338,738.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-03Vivo Capital VIII, LLC10% Share HolderSell36,400.0013.80502,320.00339,480.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020008792/0001213900-20-008792-index.htm
2020-04-17PERCEPTIVE ADVISORS LLC10% Share HolderBuy1,071,428.0014.0014,999,992.003,659,381.00https://www.sec.gov/Archives/edgar/data/1658247/000089924320010940/0000899243-20-010940-index.htm
2020-03-09Vivo Capital VIII, LLC10% Share HolderSell48.0019.50936.00375,880.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020006030/0001213900-20-006030-index.htm
2020-02-10Vivo Capital VIII, LLC10% Share HolderSell200.0021.404,280.00375,928.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-07Vivo Capital VIII, LLC10% Share HolderSell157.0022.003,454.00376,128.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020003326/0001213900-20-003326-index.htm
2020-02-04Vivo Capital VIII, LLC10% Share HolderSell357.0022.808,139.60376,285.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002831/0001213900-20-002831-index.htm
2020-01-31Vivo Capital VIII, LLC10% Share HolderSell143.0021.703,103.10376,642.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-30Vivo Capital VIII, LLC10% Share HolderSell201.0022.104,442.10376,785.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2020-01-29Vivo Capital VIII, LLC10% Share HolderSell369.0022.208,191.80376,986.00https://www.sec.gov/Archives/edgar/data/1658247/000121390020002314/0001213900-20-002314-index.htm
2019-03-20Vivo Capital VIII, LLC10% Share HolderSell40,407.0022.25899,055.75377,355.00https://www.sec.gov/Archives/edgar/data/1658247/000161577419004434/0001615774-19-004434-index.htm
2018-07-20Vivo Capital VIII, LLC10% Share HolderBuy7,137.0017.00121,329.00417,762.00https://www.sec.gov/Archives/edgar/data/1658247/000161577418006729/0001615774-18-006729-index.htm
2020-07-16Richard Scott StruthersPresident & CEOSell17,500.0014.46253,107.75890,805.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2020-07-15Richard Scott StruthersPresident & CEOSell17,500.0015.30267,722.00908,305.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120042897/0001209191-20-042897-index.htm
2019-06-215AM Ventures IV, L.P.InsiderSell10,000.0022.20222,000.0094,489.00https://www.sec.gov/Archives/edgar/data/1658247/000110465919037468/0001104659-19-037468-index.htm
2020-04-28WENDALL WIERENGADirectorBuy25,329.000.7318,490.1799,846.00https://www.sec.gov/Archives/edgar/data/1658247/000120919120026196/0001209191-20-026196-index.htm